Cystic Fibrosis Clinical Trial
Official title:
Long Term Safety and Tolerability Study of Open-Label Liposomal Amikacin for Inhalation (ARIKACE™) in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa
The purpose of this study is to evaluate the long term safety and tolerability of Liposomal Amikacin for Inhalation (LAI) 590 mg once daily (QD) in Cystic Fibrosis patients with chronic infection due to pseudomonas aeruginosa. This long-term, open-label, multi-cycle extension study enrolled subjects who had successfully completed study TR02-108, were compliant with the study protocol, and did not meet any of the listed study discontinuation criteria. The safety and tolerability of LAI were evaluated for up to approximately 2 years.
This was a long-term, open-label, multi-cycle extension study for patients in the Phase 3
study TR02-108 and TR02-109 who had successfully completed the 168-day study period and met
study safety criteria. As this was a safety and tolerability long-term extension study, no
sample size calculations were performed. All patients who completed TR02-108, were compliant
with the study protocol, and did not meet any of the criteria listed for study
discontinuation (safety reasons or non-compliance) were able to participate in this
open-label study.
The end of study visit for TR02-108 was to serve as the baseline study visit (Day 1) for
TR02-110 if the patient had signed the informed consent at least 4 days prior to the end of
study visit and met all safety criteria for TR02-110. If the end of study visit was not used
as the baseline visit, a separate baseline visit (Day 1) was to be performed within 14 days
of completing TR02-108.
Patients were to receive a delivered dose of 590 mg LAI QD via a PARI Investigational eFlow®
Nebulizer System (eFlow®) for 28 days followed by a 28-day off-treatment period. This cycle
(28 days on treatment, 28 days off treatment) was to be repeated for up to 12 cycles. The
study was implemented as 2 consecutive extension periods, each consisting of 48 weeks
(approximately 12 months). Patients were re-consented for the second extension period at the
completion of the first extension period. The total study period was up to 96 weeks
(approximately 2 years).
During the first 28 days of treatment, patients were evaluated at the study site bi-weekly
for safety, tolerability and efficacy. Thereafter, for the duration of the study, patients
were evaluated at the study site on the first and last days of dosing during the on-treatment
periods. During the study, starting with the off-treatment period of Cycle 1, patients were
contacted by telephone once during every 28-day period to assess safety. A final site visit
occurred 28 days after last dose of LAI. Arikace™, Arikayce™,Liposomal Amikacin for
Inhalation (LAI), and Amikacin Liposome Inhalation Suspension (ALIS) may be used
interchangeably throughout this study and other studies evaluating amikacin liposome
inhalation suspension.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04696198 -
Thoracic Mobility in Cystic Fibrosis Care
|
N/A | |
Completed |
NCT00803205 -
Study of Ataluren (PTC124™) in Cystic Fibrosis
|
Phase 3 | |
Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
Completed |
NCT03601637 -
Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del
|
Phase 3 | |
Terminated |
NCT02769637 -
Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)
|
||
Recruiting |
NCT06030206 -
Lung Transplant READY CF 2: A Multi-site RCT
|
N/A | |
Recruiting |
NCT06032273 -
Lung Transplant READY CF 2: CARING CF Ancillary RCT
|
N/A | |
Recruiting |
NCT06012084 -
The Development and Evaluation of iCF-PWR for Healthy Siblings of Individuals With Cystic Fibrosis
|
N/A | |
Recruiting |
NCT06088485 -
The Effect of Bone Mineral Density in Patients With Adult Cystic Fibrosis
|
||
Recruiting |
NCT05392855 -
Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF)
|
N/A | |
Recruiting |
NCT04056702 -
Impact of Triple Combination CFTR Therapy on Sinus Disease.
|
||
Recruiting |
NCT04039087 -
Sildenafil Exercise: Role of PDE5 Inhibition
|
Phase 2/Phase 3 | |
Completed |
NCT04058548 -
Clinical Utility of the 1-minute Sit to Stand Test as a Measure of Submaximal Exercise Tolerance in Patients With Cystic Fibrosis During Acute Pulmonary Exacerbation
|
N/A | |
Completed |
NCT04038710 -
Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.
|
||
Completed |
NCT03637504 -
Feasibility of a Mobile Medication Plan Application in CF Patient Care
|
N/A | |
Recruiting |
NCT03506061 -
Trikafta in Cystic Fibrosis Patients
|
Phase 2 | |
Completed |
NCT03566550 -
Gut Imaging for Function & Transit in Cystic Fibrosis Study 1
|
||
Recruiting |
NCT04828382 -
Prospective Study of Pregnancy in Women With Cystic Fibrosis
|
||
Completed |
NCT04568980 -
Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
|
||
Recruiting |
NCT04010253 -
Impact of Bronchial Drainage Technique by the Medical Device Simeox® on Respiratory Function and Symptoms in Adult Patients With Cystic Fibrosis
|
N/A |